Stockscreener 앱 받기
29.65
1.56%
-0.47
시간 외 거래:
29.65
전일 마감가:
$30.12
열려 있는:
$29.29
하루 거래량:
1.07M
Relative Volume:
1.26
시가총액:
$2.58B
수익:
$399.58M
순이익/손실:
$-54.04M
주가수익비율:
-39.53
EPS:
-0.75
순현금흐름:
$40.13M
1주 성능:
-10.59%
1개월 성능:
-14.70%
6개월 성능:
-12.90%
1년 성능:
+33.80%
1일 변동 폭
$28.52
$30.16
1주일 범위
$28.52
$34.19
52주 변동 폭
$18.61
$47.32
Veracyte Inc Stock (VCYT) Company Profile
명칭
Veracyte Inc
전화
(650) 243-6300
주소
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
VCYT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
29.65 | 2.58B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
497.60 | 196.14B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
205.00 | 150.17B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
419.95 | 34.36B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
116.98 | 33.45B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
176.30 | 31.62B | 15.41B | 1.37B | 2.11B | 7.50 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-20 | 개시 | Craig Hallum | Buy |
| 2024-12-05 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-16 | 개시 | UBS | Buy |
| 2024-10-10 | 개시 | Guggenheim | Buy |
| 2024-02-23 | 재확인 | Needham | Buy |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-11-18 | 재개 | Goldman | Buy |
| 2021-06-15 | 개시 | Raymond James | Outperform |
| 2021-02-18 | 재개 | Needham | Buy |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | 개시 | Morgan Stanley | Underweight |
| 2019-07-31 | 개시 | Lake Street | Buy |
| 2019-07-02 | 개시 | Needham | Buy |
| 2018-11-29 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-07 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-11-07 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | 재개 | BTIG Research | Buy |
| 2016-11-14 | 재개 | Leerink Partners | Outperform |
| 2015-12-18 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-11 | 재확인 | Leerink Partners | Outperform |
| 2013-11-26 | 개시 | William Blair | Outperform |
모두보기
Veracyte Inc 주식(VCYT)의 최신 뉴스
Veracyte (VCYT) Introduces AI-Powered Cancer Detection – Faster and More Accurate Than Ever! - Insider Monkey
9 AI News and Ratings on Investors’ Radar - Insider Monkey
Craig-Hallum bullish on Veracyte, initiates with a Buy - MSN
Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade - Yahoo
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer - 01net
Veracyte Cancer Diagnostic Platform Shows Higher Specificity Than Blood Tests - Marketscreener.com
Veracyte (VCYT) Shares Cross Above 200 DMA - Nasdaq
Veracyte says new data demonstrate accuracy of WGS-based platform - TipRanks
New Data Demonstrate Accuracy Of Veracyte's Whole-Genome Sequencing-Based Mrd Testing Platform For Muscle-Invasive Bladder Cancer - Marketscreener.com
Revolutionary Blood Test Detects Cancer Return 3 Months Earlier Than Imaging - Stock Titan
5 Analysts Assess Veracyte: What You Need To Know - Benzinga
Craig-Hallum initiates Veracyte stock with Buy, sets $45 target By Investing.com - Investing.com South Africa
Craig-Hallum initiates Veracyte stock with Buy, sets $45 target - Investing.com India
Craig-Hallum Initiates Veracyte at Buy With $45 Price Target -March 20, 2025 at 07:28 am EDT - Marketscreener.com
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25 - BioSpace
Veracyte's Decipher, MRD tests highlights to be presented at EAU25 -March 19, 2025 at 05:05 pm EDT - Marketscreener.com
Veracyte's Cancer Detection Tests Prove Powerful in Major Clinical StudiesNew Product Coming - StockTitan
Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally? - Yahoo Finance
Veracyte’s chief commercial officer John Leite sells $234,629 in stock By Investing.com - Investing.com Canada
Veracyte’s chief commercial officer John Leite sells $234,629 in stock - Investing.com
Veracyte (VCYT) Surged on Reporting Strong Earnings - Insider Monkey
Veracyte Inc to Host Earnings Call - ACCESS Newswire
Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality - Simply Wall St
29,779 Shares in Veracyte, Inc. (NASDAQ:VCYT) Purchased by Proficio Capital Partners LLC - Defense World
Veracyte at Raymond James Conference: Strategic Expansion and Growth By Investing.com - Investing.com Australia
Veracyte at Raymond James Conference: Strategic Expansion and Growth - Investing.com India
Insider Sell: Phillip Febbo Sells Shares of Veracyte Inc (VCYT) - GuruFocus.com
Principal Financial Group Inc. Has $1.29 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Veracyte, Inc. (NASDAQ:VCYT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough - Simply Wall St
Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Truist Financial Corp - Defense World
Veracyte's (NASDAQ:VCYT) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
Veracyte (NASDAQ:VCYT) Stock Price Expected to Rise, UBS Group Analyst Says - MarketBeat
Veracyte (NASDAQ:VCYT) Given Buy Rating at Needham & Company LLC - MarketBeat
Decoding Veracyte Inc (VCYT): A Strategic SWOT Insight - GuruFocus
ARK Investment Management LLC Reduces Holdings in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Veracyte (NASDAQ:VCYT) Trading 9.9% Higher on Analyst Upgrade - MarketBeat
Guggenheim Reaffirms Buy Rating for Veracyte (NASDAQ:VCYT) - MarketBeat
Phocas Financial Corp. Reduces Stake in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Veracyte (NASDAQ:VCYT) Shares Gap Down Following Weak Earnings - MarketBeat
VERACYTE, INC. SEC 10-K Report - TradingView
Rhumbline Advisers Purchases 675 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World
StockNews.com Downgrades Veracyte (NASDAQ:VCYT) to Hold - Defense World
Veracyte (NASDAQ:VCYT) Cut to "Hold" at StockNews.com - MarketBeat
Investor Network: Veracyte Inc to Host Earnings Call - ACCESS Newswire
Veracyte’s Strong Market Position and Growth Potential Drive Buy Rating - TipRanks
Veracyte Inc (VCYT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
1.76%
자본화:
|
볼륨(24시간):